Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study

Stephan Matthaei, Matthew Reaney, Chantal Mathieu, Claes-Göran Ostenson, Thure Krarup, Bruno Guerci, Jacek Kiljanski, Helmut Petto, David Bruhn, Michael Theodorakis

11 Citationer (Scopus)

Abstract

Changes to Treatment and Outcomes in Patients with Type 2 Diabetes Initiating Injectable Therapy (CHOICE) is a European prospective, observational cohort study assessing time to, and factors associated with, a significant change in therapy after type 2 diabetes patients initiate their first injectable glucose-lowering therapy, and these patients' clinical outcomes over 24 months. The authors report baseline data and factors associated with the injectable treatment regimen.
OriginalsprogEngelsk
TidsskriftDiabetes Therapy
Vol/bind3
Udgave nummer1
Sider (fra-til)6
ISSN1869-6953
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study'. Sammen danner de et unikt fingeraftryk.

Citationsformater